{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:15:55Z","timestamp":1776413755840,"version":"3.51.2"},"reference-count":43,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012513","name":"CIBERCV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Atrial fibrillation (AF) is a progressive condition characterized by atrial remodelling and dysfunction. This systematic review explores biomarkers that predict new-onset AF, highlighting their potential to improve early diagnosis and risk stratification in high-risk patients, and prevention of stroke and major adverse cardiovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a literature search of studies published between January 2014 and November 2025 in PubMed, Scopus, Web of Science, and Google Scholar, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Studies analysing specific populations and patients with prior or postoperative AF were excluded. Quality was assessed using the Newcastle\u2013Ottawa scale. Effect sizes were expressed as hazard ratio (HR) with 95% confidence intervals (CIs). We included 10 cohort studies comprising 472 581patients and 35 271 (7.5%) new-onset AF. Overall, 18 biomarkers were associated with an increased risk of AF, most notably N-terminal pro-B-type natriuretic peptide (NT-proBNP) and soluble vascular cell adhesion molecule-1 (sVCAM-1). Conversely, nine biomarkers were associated with a lower AF incidence, such as ADAMTS13 (HR 0.78, 95% CI 0.70\u20130.88). A meta-analysis of NT-proBNP demonstrated its association with a higher incidence of AF (HR 1.37, 95% CI 1.19\u20131.59) with high heterogeneity (I2 = 80%; P &amp;lt; 0.01), and lipoprotein(a) Lp(a) was associated with a significant 3% increase in AF incidence per 20\u2005mg\/dL increment. Two networks were constructed according to whether biomarkers were associated with a higher or lower incidence of AF, visualizing their connection with other biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Well-known biomarkers, such as NT-proBNP, and others not yet incorporated into clinical practice, such as Lp(a) and sVCAM-1, could play a role in the diagnosis and preventive management of AF. Large-scale prospective studies are needed to validate and optimize their diagnostic utility in predicting new-onset AF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag061","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:45:08Z","timestamp":1769604308000},"source":"Crossref","is-referenced-by-count":1,"title":["Identification of biomarkers for predicting new-onset atrial fibrillation: a systematic review and meta-analysis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2115-2703","authenticated-orcid":false,"given":"Dar\u00edo","family":"Mandaglio-Collados","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigaci\u00f3n Biosanitaria (IMIB-Arrixaca), CIBERCV , Murcia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4528-0845","authenticated-orcid":false,"given":"Mar\u00eda Pilar","family":"Ramos-Bratos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigaci\u00f3n Biosanitaria (IMIB-Arrixaca), CIBERCV , Murcia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-6241","authenticated-orcid":false,"given":"Jos\u00e9 Miguel","family":"Rivera-Caravaca","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigaci\u00f3n Biosanitaria (IMIB-Arrixaca), CIBERCV , Murcia ,","place":["Spain"]},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John and Moores University and Liverpool Heart & Chest Hospital , Liverpool ,","place":["UK"]},{"name":"Faculty of Nursing, University of Murcia , Murcia ,","place":["Spain"]},{"name":"Multidisciplinary Institute of Biomarkers Research (UmuBi), University of Murcia , Murcia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-4864","authenticated-orcid":false,"given":"Eva","family":"Soler-Espejo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigaci\u00f3n Biosanitaria (IMIB-Arrixaca) , Murcia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4945-6602","authenticated-orcid":false,"given":"Vanessa","family":"Rold\u00e1n","sequence":"additional","affiliation":[{"name":"Multidisciplinary Institute of Biomarkers Research (UmuBi), University of Murcia , Murcia ,","place":["Spain"]},{"name":"Department of Hematology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigaci\u00f3n Biosanitaria (IMIB-Arrixaca) , Murcia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John and Moores University and Liverpool Heart & Chest Hospital , Liverpool ,","place":["UK"]},{"name":"Department of Clinical Medicine, Aalborg University , Aalborg","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8458-4351","authenticated-orcid":false,"given":"Raquel","family":"L\u00f3pez-G\u00e1lvez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigaci\u00f3n Biosanitaria (IMIB-Arrixaca), CIBERCV , Murcia ,","place":["Spain"]},{"name":"Multidisciplinary Institute of Biomarkers Research (UmuBi), University of Murcia , Murcia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigaci\u00f3n Biosanitaria (IMIB-Arrixaca), CIBERCV , Murcia ,","place":["Spain"]},{"name":"Multidisciplinary Institute of Biomarkers Research (UmuBi), University of Murcia , Murcia ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026021900161421000_zwag061-B1","doi-asserted-by":"crossref","first-page":"100786","DOI":"10.1016\/j.lanepe.2023.100786","article-title":"Atrial fibrillation: epidemiology, screening and digital health","volume":"37","author":"Linz","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026021900161421000_zwag061-B2","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/j.jacc.2014.04.019","article-title":"Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices","volume":"63","author":"Charitos","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026021900161421000_zwag061-B3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.amjmed.2021.01.017","article-title":"Clinical outcomes in asymptomatic and symptomatic atrial fibrillation presentations in GARFIELD-AF: implications for AF screening","volume":"134","author":"Gibbs","year":"2021","journal-title":"Am J Med"},{"key":"2026021900161421000_zwag061-B4","doi-asserted-by":"crossref","first-page":"euae204","DOI":"10.1093\/europace\/euae204","article-title":"Atrial cardiomyopathy revisited\u2014evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS)","volume":"26","author":"Goette","year":"2024","journal-title":"Europace"},{"key":"2026021900161421000_zwag061-B5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.recesp.2024.02.009","article-title":"Practical approach for atrial cardiomyopathy characterization in patients with atrial fibrillation","volume":"77","author":"La Rosa","year":"2024","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026021900161421000_zwag061-B6","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1093\/eurheartj\/ehae611","article-title":"Biomarker-based prediction of sinus rhythm in atrial fibrillation patients: the EAST-AFNET 4 biomolecule study","volume":"45","author":"Fabritz","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021900161421000_zwag061-B7","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021900161421000_zwag061-B8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/europace\/euac260","article-title":"Exploring the incremental utility of circulating biomarkers for robust risk prediction of incident atrial fibrillation in European cohorts using regressions and modern machine learning methods","volume":"25","author":"Toprak","year":"2023","journal-title":"Europace"},{"key":"2026021900161421000_zwag061-B9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12170-025-00760-1","article-title":"Lipoprotein (a) as a causal risk factor for cardiovascular disease","volume":"19","author":"Doherty","year":"2025","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"2026021900161421000_zwag061-B10","doi-asserted-by":"crossref","first-page":"102343","DOI":"10.1016\/j.jacadv.2025.102343","article-title":"Association of lipoprotein (a) with atrial fibrillation in the Framingham heart study","volume":"4","author":"Hategeka","year":"2025","journal-title":"JACC Adv"},{"key":"2026021900161421000_zwag061-B11","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein (a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026021900161421000_zwag061-B12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/clinchem\/hvaa298","article-title":"Biomarkers for risk assessment in atrial fibrillation","volume":"67","author":"Berg","year":"2021","journal-title":"Clin Chem"},{"key":"2026021900161421000_zwag061-B13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"bmj"},{"key":"2026021900161421000_zwag061-B14","first-page":"4","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Chandler","year":"2019"},{"key":"2026021900161421000_zwag061-B15","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/jn\/nxab016","article-title":"Plasma \u03c9-3 and \u03c9-6 PUFA concentrations and risk of atrial fibrillation: the multi-ethnic study of atherosclerosis","volume":"151","author":"Garg","year":"2021","journal-title":"J Nutr"},{"key":"2026021900161421000_zwag061-B16","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.amjcard.2019.03.017","article-title":"Serum metabolomics and incidence of atrial fibrillation (from the atherosclerosis risk in communities study)","volume":"123","author":"Alonso","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026021900161421000_zwag061-B17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/eurjpc\/zwaf063","article-title":"Elevated lipoprotein(a) levels linked to new-onset atrial fibrillation: insights from a retrospective cohort study","volume":"32","author":"Awad","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026021900161421000_zwag061-B18","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/heartjnl-2022-321959","article-title":"Inflammatory proteomics profiling for prediction of incident atrial fibrillation","volume":"109","author":"B\u00f6rschel","year":"2023","journal-title":"Heart"},{"key":"2026021900161421000_zwag061-B19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2019.01.010","article-title":"Peripheral blood metabolite profiles associated with new onset atrial fibrillation","volume":"211","author":"Harskamp","year":"2019","journal-title":"Am Heart J"},{"key":"2026021900161421000_zwag061-B20","doi-asserted-by":"crossref","first-page":"e010976","DOI":"10.1161\/JAHA.118.010976","article-title":"Proteomic profiling and risk of new-onset atrial fibrillation\u2014Framingham heart study","volume":"8","author":"Ko","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026021900161421000_zwag061-B21","doi-asserted-by":"crossref","first-page":"e1146","DOI":"10.1016\/j.hrthm.2025.08.001","article-title":"Lipoprotein (a) elevation independently associates with incident atrial fibrillation irrespective of inflammatory status","volume":"22","author":"Li","year":"2025","journal-title":"Heart Rhythm"},{"key":"2026021900161421000_zwag061-B22","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/pace.12969","article-title":"Association between heat shock protein-60 and development of atrial fibrillation: results from the multi-ethnic study of atherosclerosis (MESA)","volume":"39","author":"Maan","year":"2016","journal-title":"Pace-Pacing Clin Electrophysiol"},{"key":"2026021900161421000_zwag061-B23","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/heartjnl-2014-307015","article-title":"Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults","volume":"101","author":"Macheret","year":"2015","journal-title":"Heart"},{"key":"2026021900161421000_zwag061-B24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamacardio.2017.0064","article-title":"Association between vascular cell adhesion molecule 1 and atrial fibrillation","volume":"2","author":"Willeit","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026021900161421000_zwag061-B25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.aje.a115184","article-title":"The atherosclerosis risk in communit (ARIC) study: design and objectives","volume":"129","author":"Investigators","year":"1989","journal-title":"Am J Epidemiol"},{"key":"2026021900161421000_zwag061-B26","doi-asserted-by":"crossref","first-page":"696-i","DOI":"10.1093\/ije\/dyx239","article-title":"Cohort profile: the national FINRISK study","volume":"47","author":"Borodulin","year":"2018","journal-title":"Int J Epidemiol"},{"key":"2026021900161421000_zwag061-B27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/aje\/kwf113","article-title":"Multi-ethnic study of atherosclerosis: objectives and design","volume":"156","author":"Bild","year":"2002","journal-title":"Am J Epidemiol"},{"key":"2026021900161421000_zwag061-B28","first-page":"458","article-title":"The measurement to understand reclassification of disease of Cabarrus\/Kannapolis (MURDOCK) study community registry and biorepository","volume":"4","author":"Bhattacharya","year":"2012","journal-title":"Am J Transl Res"},{"key":"2026021900161421000_zwag061-B29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2105\/AJPH.47.4_Pt_2.4","article-title":"Coronary heart disease in the Framingham study","volume":"47","author":"Dawber","year":"1957","journal-title":"Am J Public Health Nations Health"},{"key":"2026021900161421000_zwag061-B30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/1047-2797(91)90005-W","article-title":"The cardiovascular health study: design and rationale","volume":"1","author":"Fried","year":"1991","journal-title":"Ann Epidemiol"},{"key":"2026021900161421000_zwag061-B31","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.STR.25.8.1593","article-title":"Alcohol consumption and carotid atherosclerosis: evidence of dose-dependent atherogenic and antiatherogenic effects. Results from the Bruneck Study","volume":"25","author":"Kiechl","year":"1994","journal-title":"Stroke"},{"key":"2026021900161421000_zwag061-B32","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"2026021900161421000_zwag061-B33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ehf2.13703","article-title":"NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials","volume":"9","author":"Werhahn","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026021900161421000_zwag061-B34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/heartjnl-2024-324685","article-title":"Association between NT-proBNP levels and risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies","volume":"111","author":"Wang","year":"2025","journal-title":"Heart"},{"key":"2026021900161421000_zwag061-B35","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026021900161421000_zwag061-B36","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.repc.2020.07.009","article-title":"Increased serum interleukin-6 level as a predictive biomarker for atrial fibrillation: a systematic review and meta-analysis","volume":"39","author":"Zhou","year":"2020","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"2026021900161421000_zwag061-B37","doi-asserted-by":"crossref","first-page":"100821","DOI":"10.1016\/j.bj.2024.100821","article-title":"Endothelial activation, cell-cell interactions, and inflammatory pathways in postoperative atrial fibrillation following cardiac surgery","volume":"48","author":"L\u00f3pez-G\u00e1lvez","year":"2024","journal-title":"Biomed J"},{"key":"2026021900161421000_zwag061-B38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1359-6101(02)00045-X","article-title":"Macrophage inflammatory protein-1","volume":"13","author":"Menten","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026021900161421000_zwag061-B39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10456-024-09922-y","article-title":"CCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation","volume":"27","author":"Chang","year":"2024","journal-title":"Angiogenesis"},{"key":"2026021900161421000_zwag061-B40","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12887-024-04849-1","article-title":"Dolphin CONTINUE: a multi-center randomized controlled trial to assess the effect of a nutritional intervention on brain development and long-term outcome in infants born before 30 weeks of gestation","volume":"24","author":"Janson","year":"2024","journal-title":"BMC Pediatr"},{"key":"2026021900161421000_zwag061-B41","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-023-01638-7","article-title":"RNA modification in cardiovascular disease: implications for therapeutic interventions","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026021900161421000_zwag061-B42","doi-asserted-by":"crossref","first-page":"e016737","DOI":"10.1161\/JAHA.120.016737","article-title":"Altered acylcarnitine metabolism is associated with an increased risk of atrial fibrillation","volume":"9","author":"Smith","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026021900161421000_zwag061-B43","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.3390\/nu16223937","article-title":"The cardioprotective effects of polyunsaturated fatty acids depends on the balance between their anti-and pro-oxidative properties","volume":"16","author":"Sidorkiewicz","year":"2024","journal-title":"Nutrients"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag061\/66634223\/zwag061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag061\/66634223\/zwag061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:16:22Z","timestamp":1771478182000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag061\/8444749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag061","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"zwag061"}}